Click here to read the articles and download the PDF

Pharmaceutical Commerce - December 2023

How drugmakers can better harness real-world evidence to drive their clinical and commercial objectives, while also providing greater clarity for healthcare providers and improved access to therapy for the patients they serve.

The Business Case for RWE

While new forms of pharmacy continue to surface beyond brick-and-mortar retail, a look at what is driving this shift in perspective—and "pharmacies of the future"—is warranted.

Who Moved My Prescription?

Methods that pharma companies can use to make the hub more personalized and experiential.

Transforming the Patient Hub into a Hub of Patient Centricity

Articles

Conference keynote offers an industry outlook, including new commercialization challenges.

Trade & Channel Strategies 2023: A Dive into Pharmacy and the Distribution Channel

Phase III INTerpath-002 trial will evaluate the novel individualized neoantigen therapy V940 (mRNA-4157) with Keytruda (pembrolizumab) as an adjuvant treatment for patients with non-small cell lung cancer.

Merck and Moderna Announce Phase III Trial of Combination Therapy for Non-Small Cell Lung Cancer

To rebuild trust, companies should utilize a customer-centric approach, focusing on transparent and neutral content incorporating medical expertise and regularly seeking HCP feedback.

 Is Trust the Secret Ingredient for Digital Product Success?

Adults and children aged 1 year and older are eligible for the IV formulation of 
Cresemba for invasive aspergillosis and invasive mucormycotic, whereas the prescribed capsule is only indicated for adults and children 6 years of age and older.

Cresemba Granted Expanded Indication by FDA for Pediatric Patients With Invasive Aspergillosis, Invasive Mucormycosis

The rise in demand represents the third consecutive month of year-on-year growth. 

October Air Freight Numbers Indicate a Continued Increase in Demand, Says IATA

FDA approves bluebird bio’s Lyfgenia and Vertex Pharmaceuticals' and CRISPR Therapeutics’ Casgevy for the treatment of sickle cell disease, which affects approximately 100,000 people in the United States.

Lyfgenia, Casgevy Become First Cell-Based Gene Therapies to Gain FDA Approval for Sickle Cell Disease

Study analyzes and predicts how conditions in research and development can be predicted via computer simulation.

A Guide on Determining Stability of Molecular Crystals in Pharmaceutical Drug Development

PrEPVacc tested two different combinations of vaccines to determine whether either can prevent HIV infection in populations at risk of acquiring the virus.

Limited Evidence of Efficacy Halts Study of Novel HIV Vaccine, Oral PrEP

December's installment reinforces the publication's commitment to covering the latest updates on patient support.

Patients are the Priority

Introducing a new style and feel to Pharma Commerce.

Featured Content

Pharmaceutical Commerce - December 2023

The Business Case for RWE

Who Moved My Prescription?

Transforming the Patient Hub into a Hub of Patient Centricity